A phase Ib open-label dose escalation and expansion study to investigate the safety pharmacokinetics pharmacodynamics and clinical activity of GSK525762 in combination with androgen deprivation therapy and other agents in subjects with castrate-resistant prostate cancer (CRPC)
Brief description of study
If you have been diagnosed with prostate cancer, you may qualify to participate in a clinical trail. The main goal of this phase 1b study is to determine the maximum tolerated dose and recommended phase 2 dose based on safety, tolerability, pharmacokinetic, and efficient profiles for the based on safety, tolerability, pharmacokinetic, and efficacy profiles for the investigational drug, GSK525762 (an androgen receptor inhibitor that targets bromodomain and extraterminal domains proteins) in combination with abiraterone (an androgen synthesis inhibitor) or enzalutamide (a non-steroidal antiandrogen).
Clinical Study Identifier: s17-00418
ClinicalTrials.gov Identifier: NCTs17-00418
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
